Loading clinical trials...
Loading clinical trials...
A Prospective, Observational Cohort Study to Evaluate the Clinical Impact of Novel Monoclonal Antibodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian Clinical Practice
Conditions
Interventions
"novel" MAB (alone or in combination)
Locations
61
Italy
Istituto Oncologico del Mediterraneo SPA - Oncologico
Viagrande, Catania, Italy
Ospedale SS. Cosma e Damiano - Ospedale San Jacopo - SOS Oncoematologia ed ematologia clinica
Pescia, Pistoia, Italy
A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia
Alessandria, Italy
AOU Ospedali Riuniti - Clinica di Ematologia
Ancona, Italy
Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico
Avellino, Italy
IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati
Aviano, Italy
Start Date
December 27, 2023
Primary Completion Date
October 1, 2038
Completion Date
October 1, 2038
Last Updated
December 29, 2025
NCT06534437
NCT05312801
NCT06705530
NCT06318884
NCT02772198
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions